2020
DOI: 10.1111/ijcp.13935
|View full text |Cite
|
Sign up to set email alerts
|

C‐reactive protein and procalcitonin levels in prostate cancer

Abstract: Aim Prostate cancer (PCa) is one of the most common cancers among men in the world. Prostate‐specific antigen is the most used biomarker for PCa diagnosis. In this study, we aimed to measure the procalcitonin (PCT) and C‐reactive protein (CRP) levels in patients with PCa. Methods The patients who underwent transrectal prostate biopsy and transurethral prostate surgery in the last 4 years were included in the study. The patients were divided into two groups according to the pathology reports, group1; benign pro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 15 publications
0
1
0
Order By: Relevance
“…Tracking and precisely determining the CRP level in the human body over time could allow us to evaluate the inflammation progression and tumor aggressiveness and monitor the treatment outcomes. Therefore, CRP is an important biomarker for cancer diagnosis and prognosis. …”
Section: Introductionmentioning
confidence: 99%
“…Tracking and precisely determining the CRP level in the human body over time could allow us to evaluate the inflammation progression and tumor aggressiveness and monitor the treatment outcomes. Therefore, CRP is an important biomarker for cancer diagnosis and prognosis. …”
Section: Introductionmentioning
confidence: 99%